Merkel Positron Emission Tomography (PET) Protocol (MP3)
A Phase II Efficacy Study of Chemo-Radiotherapy in PET Stage II and III Merkel Cell Carcinoma of the Skin
Sponsor: Trans Tasman Radiation Oncology Group
A PHASE2 clinical study on Merkel Cell Carcinoma, this trial is completed. The trial is conducted by Trans Tasman Radiation Oncology Group and has accumulated 8 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
May 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Trans Tasman Radiation Oncology Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Brisbane, Australia , Campbelltown, Australia , Geelong, Australia , Herston, Australia , Liverpool, Australia , Melbourne, Australia , Nedlands, Australia , Sydney, Australia , Toowoomba, Australia , Tugun, Australia and 2 more locations